Zydus Cadila has received final approval from the US health regulator to market doxycycline tablets, used for the treatment of different types of bacterial infections such as acne and eye infection.
The company has received approval from the US Food and Drug Administration (USFDA) to market the drug in strengths of 50 mg, 75 mg, 100 mg and 150 mg, Zydus Cadila said in a BSE filing today.
The company will manufacture the drug at the group’s formulations facility at the pharma SEZ in Ahmedabad.
It has more than 155 approvals and has so far filed over 300 abbreviated new drug applications (ANDAs) since it had commenced filings in 2003-04.
Cadila Healthcare shares were trading up by 2.3 per cent at Rs 477.90 on the BSE.